Among small molecular caspase-3 probes, which demonstrate favorable pharmacokinetics and tumor penetration properties, such as [18F]-ICMT-11 and [18F]-ML-10, SNR remains the primary barrier to clinical application [29–30, 36]. This evidence concerns the gene CASP3 and neoplasm.